Vakiener Victoria
Director at ARWR; Chief Commercial Officer at Epizyme, Inc.
- Sold, on record
- $1.2M
- Dollars the filings state
- Form 4 sales
- 7
- Latest Dec 19, 2025
- Form 144 notices
- 4
- Proposed sales
- Companies
- 2
- Filed as an executive or holder
Companies
- ARWRARROWHEAD PHARMACEUTICALS, INC.Director
- Epizyme, Inc.Chief Commercial Officer
Sales by reason
Form 4 sales per month, last 12 months.
Sales by company
- ARWR27,103 shares
- Epizyme, Inc.1,416 shares
Shares sold, every Form 4 sale on record.
Timeline
- 1 Form 4 sale ARWRNo planSep 28, 2023 2023
Sold 1,550 shares at $26.33 ($41k)
Vakiener Victoria, Director
No 10b5-1 planSold 6.7% of holdings ($613k position)21,734 shares leftFirst sale on recordFollows a Form 144Filing
- 2 Form 144 notice ARWRNoticeJan 11, 2024 +105 days
Filed to sell 4,720 shares ($180k)
Vakiener Victoria, Officer
10b5-1 planFiling
- 3 Form 4 sale ARWRRoutineJan 11, 2024 same day
Sold 4,720 shares at $38.10 ($180k)
Vakiener Victoria, Director
10b5-1 planSold 12.9% of holdings ($1.4M position)32,001 shares leftFollows a Form 144Filing
- 4 Form 144 notice ARWRNoticeMay 2, 2024 +112 days
Filed to sell 1,799 shares ($42k)
Vakiener Victoria, Officer
10b5-1 planFiling
- 5 Form 4 sale ARWRRoutineMay 2, 2024 same day
Sold 1,799 shares at $23.31 ($42k)
Vakiener Victoria, Director
10b5-1 planSold 5.6% of holdings ($746k position)30,205 shares leftFollows a Form 144Filing
- 6 Form 144 notice ARWRNoticeDec 16, 2024 +228 days
Filed to sell 8,994 shares ($197k)
Vakiener Victoria, Director
10b5-1 planFirst sale on recordFiling
- 7 Form 4 sale ARWRRoutineDec 16, 2024 same day
Sold 8,994 shares at $21.91 ($197k)
Vakiener Victoria, Director
10b5-1 planSold 29.8% of holdings ($662k position)21,211 shares leftFirst sale on recordFollows a Form 144Filing
- 8 Form 4 sale ARWRRoutineDec 19, 2025 +368 days
Sold 10,040 shares at $67.68 ($679k)
Vakiener Victoria, Director
10b5-1 planSold 21.9% of holdings ($3.1M position)35,723 shares left2.1x usual sizeFiling
Every transaction
Loading transactions…
Sales and notices (11)
| Source | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Dec 19, 2025 | Dec 23, 2025 | ARWR | Director | Form 4 sale | 10,040 | $679k | 21.9% | Routine | SEC |
| Dec 16, 2024 | Dec 18, 2024 | ARWR | Director | Form 4 sale | 8,994 | $197k | 29.8% | Routine | SEC |
| Dec 16, 2024 | Dec 16, 2024 | ARWR | Director | Form 144 notice | 8,994 | $197k | Notice | SEC | |
| May 2, 2024 | May 6, 2024 | ARWR | Director | Form 4 sale | 1,799 | $42k | 5.6% | Routine | SEC |
| May 2, 2024 | May 2, 2024 | ARWR | Officer | Form 144 notice | 1,799 | $42k | Notice | SEC | |
| Jan 11, 2024 | Jan 16, 2024 | ARWR | Director | Form 4 sale | 4,720 | $180k | 12.9% | Routine | SEC |
| Jan 11, 2024 | Jan 11, 2024 | ARWR | Officer | Form 144 notice | 4,720 | $180k | Notice | SEC | |
| Sep 28, 2023 | Oct 2, 2023 | ARWR | Director | Form 4 sale | 1,550 | $41k | 6.7% | No plan | SEC |
| Sep 28, 2023 | Sep 28, 2023 | ARWR | Officer | Form 144 notice | 1,550 | $41k | Notice | SEC | |
| Feb 4, 2021 | Feb 5, 2021 | Epizyme, Inc. | Chief Commercial Officer | Form 4 sale | 817 | $9k | 1.5% | Plan not stated | SEC |
| Jan 25, 2021 | Jan 27, 2021 | Epizyme, Inc. | Chief Commercial Officer | Form 4 sale | 599 | $7k | 2.1% | Plan not stated | SEC |